Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The estimate of $70 billion was $20 billion more than its previous estimate a year ago

  80% confidence

• Merck expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s

  80% confidence

• Merck expects revenues to be in the range of $65.5-$67.0 billion in 2026, representing year-over-year growth of 1% to 3%

  80% confidence

• A lower-than-expected infant immunization rate and high inventory levels in the market hurt Enflonsia sales in Q4 2025

  80% confidence

• Adjusted earnings per share are expected to be between $5.00 and $5.15 in 2026

  80% confidence

• Merck has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months

  80% confidence

• The estimate of $70 billion was more than double the peak consensus estimate for Keytruda revenues of $35 billion in 2028

  80% confidence

• Keytruda growth was negatively impacted by approximately $200 million due to the unfavorable timing of wholesaler purchases in the United States in Q4 2025

  80% confidence

• The adjusted gross margin is expected to be around 82% in 2026

  80% confidence

• In 2026, Merck expects to buy back shares worth $3 billion

  80% confidence

• Roche Holding has a Zacks Rank #3 (Hold)

  80% confidence

• Generic competition for Januvia/Janumet, Bridion and Dificid is expected to hurt revenues by approximately $2.5 billion in 2026

  80% confidence

Data points we hold from this source